The biotech community often accepts batch-to-batch variability as a given. A more effective mindset is to view it as a fundamental process design flaw. This perspective pushes for more robust, controlled processes that eliminate sources of variability, rather than just managing them with workarounds.
To manage the unreliability of animal-derived raw materials, some companies run a complete pilot process alongside GMP production solely for pre-testing incoming lots. This extreme workaround highlights the immense hidden operational costs and inefficiencies that are accepted when process inputs are not fully defined.
Animal-derived lab materials, like tissue scaffolds, suffer from massive batch variability. By producing a key structural protein recombinantly, its sequence becomes DNA-coded and consistent, just like a therapeutic drug. This approach transforms a variable, multi-component extract into a defined, single-molecule product, ensuring reproducibility.
Instead of a one-size-fits-all product, a platform strategy enables the rapid generation of protein libraries. This allows for high-throughput screening and the creation of custom-tailored 3D environments (bioinks) specific to a user's cell type. This moves the business model from selling a component to providing a bespoke solution.